热毒宁注射液联合阿奇霉素治疗儿童支原体肺炎的系统评价与Meta分析
该系统评价纳入20项RCT共1628例儿童支原体肺炎患者,评价热毒宁注射液联合阿奇霉素的疗效与安全性。Meta分析显示联合治疗在临床有效率、症状消失时间及炎症因子水平上优于对照,不良反应发生率差异有统计学意义,结论为可提高疗效且安全性较高。
要点
- 热毒宁联合阿奇霉素可提高儿童支原体肺炎临床有效率(RR=1.20)。
- 联合治疗缩短咳嗽、肺啰音消失及退热时间,降低TNF-α和IL-6水平。
- 不良反应发生率RR=0.75,差异有统计学意义,安全性较高。
核心结论
- 热毒宁注射液联合阿奇霉素治疗儿童支原体肺炎可提高临床疗效且安全性较高。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库(PubMed、EMBASE、Cochrane Library、Web of Science及CNKI、万方、维普、Sino-Med),纳入20项RCT共1628例患儿。
主要发现
- 临床有效率RR=1.20(95%CI [1.15, 1.26],I2=0%)。
- 咳嗽消失时间MD=-2.04(95%CI [-2.67, -1.41],I2=91%)。
- 肺啰音消失时间MD=-2.55(95%CI [-3.12, -1.98],I2=95%)。
- 退热时间MD=-1.93(95%CI [-2.37, -1.49],I2=92%)。
- 治疗后TNF-α水平SMD=-1.17(95%CI [-1.96, -0.39],I2=97%),IL-6水平SMD=-2.65(95%CI [-3.51, -1.78],I2=97%)。
关键数值与推荐
- 不良反应发生率RR=0.75(95%CI [0.56, 1.00],I2=0%),差异有统计学意义。
临床怎么用
- 儿童支原体肺炎可考虑热毒宁注射液联合阿奇霉素治疗,以提升疗效并缩短症状缓解时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reduning (RDN) injection is a well-known traditional Chinese medicine (TCM) preparation that can be used as an alternative to antibiotics with synergistic and toxicity-reducing effects. In China, RDN is widely used in the combined treatment of infectious diseases. OBJECTIVE: To evaluate the clinical efficacy of RDN combined with azithromycin (AZM) for the treatment of mycoplasma pneumonia (MP) among children and to determine its safety, providing an evidence-based reference for clinical treatment. METHODS: Eight databases were searched, including 4 English databases, namely, PubMed, EMBASE, the Cochrane Library, and Web of Science, and 4 Chinese databases, namely, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (CQVIP), and Sino-Med. Randomized controlled trials (RCTs) were included in which RDN was combined with AZM for the treatment of MP pediatric patients. A comprehensive search was performed from the inception of each database until April 25, 2022. RESULTS: A total of 20 studies covering 1628 children were included. Meta-analysis showed that the clinical effectiveness rate (RR = 1.20, 95% CI [1.15, 1.26], I2 = 0%), time elapsed until disappearance of cough (MD = -2.04, 95% CI [-2.67, -1.41], I2 = 91%), time elapsed until disappearance of lung rales (MD = -2.55, 95% CI [-3.12, -1.98], I2 = 95%), time elapsed until reduction of fever (MD = -1.93, 95% CI [-2.37, -1.49], I2 = 92%), TNF-α level after treatment (SMD = -1.17, 95% CI [-1.96, -0.39], I2 = 97%), and IL-6 levels after treatment (SMD = -2.65, 95% CI [-3.51, -1.78], I2 = 97%) of the combined treatment of MPP were superior to those of other methods, and incidence of adverse reactions (RR = 0.75, 95% CI [0.56, 1.00], I2 = 0%) showed statistically significant differences. CONCLUSION: RDN combined with AZM for the treatment of MP among children results in increased clinical efficacy with high safety.
引用
- Wang H, Zhao M, Liu S, et al. Efficacy and safety of reduning injection combined with azithromycin in the treatment of mycoplasma pneumonia among children: A systematic review and meta-analysis. Phytomedicine. 2022. PMID: 36029644. doi:10.1016/j.phymed.2022.154402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。